Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This study aims to quantify and follow the cumulative incidence of SARS-CoV-2 infection in the French population using serological tests and to assess the determinants of infection from Constances, E3N-E4N, ELFE-Epipage 2 and NutriNet-Santé cohorts.
Description: To assess the cumulative incidence of SARS-Cov2 infection in the general population.
Measure: Cumulative incidence of SARS-Cov2 infection in the general population. Time: 8 monthsDescription: Besides to Characterize the "immune" fraction of the population and the durability of immunity, the other secondary outcomes are: Identify associations of predictive symptoms of SARS-Cov2 infection Estimate the use of care rate in connection with a SARS-Cov2 infection Estimate the fraction of sub-clinical infections or infections not captured by the healthcare system; Study the acceptability of a mass anti-SARS-Cov2 serological test and the impact of its result, link with social inequalities in health; Estimate the individual and collective impact of containment and other barrier measures on the risk of seroconversion; Study the impact of social and territorial inequalities on the level of seroprevalence.
Measure: Characterize the "immune" fraction of the population and the durability of immunity Time: 8 months